Solid Tumors
Immatics Biotechnologies GmbH focuses its clinical development activity on solid tumors, with trials centered on recurrent and refractory disease settings. The research portfolio reflects interest in oncology and tumor-directed immunotherapy.
- Recurrent and refractory solid tumor treatment
- Anti-tumor activity
- Checkpoint inhibitor combinations
The sponsor’s trial activity includes patient populations with advanced malignancies across multiple sites in Europe.
Bispecific T-cell Engagers
The sponsor is active in bispecific T-cell engager research, including T-cell receptor-based approaches designed to direct immune activity toward tumor-associated targets. This area links immuno-oncology with antigen-specific cancer recognition.
- TCER® platforms
- PRAME-targeted therapy
- T-cell redirection
These studies reflect a therapeutic emphasis on engineered immune engagement in difficult-to-treat malignancies.
Combination Immunotherapy
Immatics also investigates combination therapy strategies that pair its investigational agents with checkpoint inhibitors, highlighting interest in enhancing immune-mediated tumor control. The research scope includes both monotherapy and combination use in oncology.
- Checkpoint blockade
- Immune response modulation
- Therapeutic synergy in cancer treatment
This area supports exploration of immune-based treatment options for patients with limited alternatives.
Early-Stage Clinical Oncology
The sponsor’s portfolio includes early-stage clinical trials assessing safety, tolerability, and anti-tumor activity in patients with advanced solid malignancies. The clinical focus remains tightly linked to translational cancer immunotherapy.
- First-in-human oncology studies
- Advanced solid malignancies
- Clinical immunology
Research activity is distributed across multiple collaborating sites and active countries.
